SOCIETYContribute expertiseContribute
INQUIRY 01 / NEUROTECHNOLOGY / RESEARCH OPEN
Neurotechnology
Brain-computer interfaces, EEG and neural sensing, rehabilitation, neuromodulation and neuroprosthetics—mapped through published evidence and conversations with people closest to the work.
Contribute to Field 01 →
LIVE INQUIRY / 01MEASUREMENT → INTERVENTION → USE
StatusResearch open / first note published
FormatFocused remote conversations
Editorial lensProof → dependable use
GeographyGlobal
FIELD NOTE / 001 / PUBLISHED
Independence is a system property.
What 3,801 hours of home use reveal about the setup, interface, care workflow and permissions surrounding an intracortical BCI.
Read the first field note ↗01
Evidence line 01
Brain-computer interfaces: from demonstration to dependable use.
Brain-computer interfaces have demonstrated communication and control in research settings. A research result, an investigational system and a scalable standard of care are different stages.
The first evidence line separates them. It follows the questions that decide whether a system can move from a controlled demonstration into dependable, safe and reachable everyday use.
02
The first working map
One frontier.
Five gates.
The first map follows brain-computer interfaces from signal to access. Each gate is both an editorial question and a place where a contributor can add evidence the map does not yet hold.
Gate 01 / Signal
Can intent be decoded reliably?
Translation risk
Neural activity varies. Decoders must stay accurate without constant researcher recalibration.
Perspective sought
Neural engineers · ML researchers · platform teams
03
Perspectives sought
We are seeking first-hand knowledge from across the translation path.
Contributors are selected for the specific experience they can add, not their title.
A neural engineer or decoding researcher
Where does performance still break under variation?
A device or platform team
What has to remain stable without a researcher present?
A participant, clinician or outcomes researcher
Which gains are meaningful enough to change a life?
A clinical, safety or regulatory leader
What evidence would be enough to proceed?
A provider, payer or market-access operator
What would make delivery sustainable and reachable?
04
Starting evidence
The inquiry starts with published evidence and develops through conversation.
01 / EvidenceClinical translation and outcome measuresAdvanced Science, 2025→02 / Home useLong-term independent speech and cursor controlNature Medicine, 2026→03 / PathwayImplanted BCI device guidanceUS Food and Drug Administration→04 / AccessTranslation and accessibility across the full chainBioScience Trends, 2026→
FIELD 01 / RESEARCH OPEN